These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28881711)

  • 1. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
    Weisberg EL; Puissant A; Stone R; Sattler M; Buhrlage SJ; Yang J; Manley PW; Meng C; Buonopane M; Daley JF; Lazo S; Wright R; Weinstock DM; Christie AL; Stegmaier K; Griffin JD
    Oncotarget; 2017 Aug; 8(32):52026-52044. PubMed ID: 28881711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
    Aikawa T; Togashi N; Iwanaga K; Okada H; Nishiya Y; Inoue S; Levis MJ; Isoyama T
    Oncotarget; 2020 Mar; 11(11):943-955. PubMed ID: 32215183
    [No Abstract]   [Full Text] [Related]  

  • 3. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
    Weisberg E; Sattler M; Manley PW; Griffin JD
    Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
    Katayama K; Noguchi K; Sugimoto Y
    Oncotarget; 2018 Sep; 9(76):34240-34258. PubMed ID: 30344940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
    J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the deubiquitinase USP10 induces degradation of SYK.
    Yang J; Meng C; Weisberg E; Case A; Lamberto I; Magin RS; Adamia S; Wang J; Gray N; Liu S; Stone R; Sattler M; Buhrlage S; Griffin JD
    Br J Cancer; 2020 Apr; 122(8):1175-1184. PubMed ID: 32015510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
    Gallogly MM; Lazarus HM
    J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
    Zhao J; Song Y; Liu D
    Biomark Res; 2019; 7():19. PubMed ID: 31528345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
    Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
    Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Gallogly MM; Lazarus HM; Cooper BW
    Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
    Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
    Yamatani K; Ai T; Saito K; Suzuki K; Hori A; Kinjo S; Ikeo K; Ruvolo V; Zhang W; Mak PY; Kaczkowski B; Harada H; Katayama K; Sugimoto Y; Myslinski J; Hato T; Miida T; Konopleva M; Hayashizaki Y; Carter BZ; Tabe Y; Andreeff M
    Transl Oncol; 2022 Apr; 18():101354. PubMed ID: 35114569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.
    Rosenberg MW; Watanabe-Smith K; Tyner JW; Tognon CE; Druker BJ; Borate U
    Oncotarget; 2020 Jul; 11(29):2807-2818. PubMed ID: 32754299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
    Green AS; Maciel TT; Hospital MA; Yin C; Mazed F; Townsend EC; Pilorge S; Lambert M; Paubelle E; Jacquel A; Zylbersztejn F; Decroocq J; Poulain L; Sujobert P; Jacque N; Adam K; So JC; Kosmider O; Auberger P; Hermine O; Weinstock DM; Lacombe C; Mayeux P; Vanasse GJ; Leung AY; Moura IC; Bouscary D; Tamburini J
    Sci Adv; 2015 Sep; 1(8):e1500221. PubMed ID: 26601252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
    Tvedt TH; Nepstad I; Bruserud Ø
    Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.